Sverre E. Kjeldsen

TL;DR: In this paper, Wang et al. presented a Kaplan-Meier plot of four unadjusted cTnT groups with different cut-points for the peak values based on clinical experience, which clearly showed the increasing risk from ≥ 1.00 μg/L, the latter threshold being similar to the one used by the universal definition.

TL;DR: The objectives of the blood pressure lowering arm (BPLA) of the Anglo Scandinavian Cardiac Outcomes Trial (ASCOT) were to compare the effect on myocardial infarction and fatal coronary heart disease, mortality, other cardiovascular endpoints and new onset diabetes of the beta-blocker atenolol+the diuretic bendroflumethiazide with the calcium-antagonist amlodipine+the angiotensinconverting enzyme (ACE) inhibitor

TL;DR: The LIFE study suggests that the mechanism of stroke prevention with losartan extends beyond its blood-pressure-lowering effects, and a reduction in stroke was an important contributor to the benefit in the composite outcome observed in patients with diabetes or isolated systolic hypertension.

TL;DR: An important part of Nordic hypertension research has long been the design and performance of large randomized outcomes trials, now remembered by their acronyms, STOP, HOT, STOP 2, CAPPP and NOR-

TL;DR: A large number of epidemiological studies have suggested an unfavorable impact of increased serum concentrations of uric acid on the future development of cardiovascular diseases in the general population and in selected groups of patients as mentioned in this paper .